{"id":18196,"date":"2026-07-15T07:22:55","date_gmt":"2026-07-15T07:22:55","guid":{"rendered":"https:\/\/mediaesthetic.com.my\/lenisna-treatment-jb\/"},"modified":"2026-08-04T14:10:55","modified_gmt":"2026-08-04T14:10:55","slug":"lenisna-treatment-jb","status":"publish","type":"page","link":"https:\/\/mediaesthetic.com.my\/zh-hant\/lenisna-treatment-jb\/","title":{"rendered":"Lenisna PDLLA + HA Treatment in JB"},"content":{"rendered":"
\n
\n
\n\n
Doctor-Led PDLLA & HA Assessment<\/div>\n\n\n\n

Doctor-Led LENISNA PDLLA + HA Treatment in Johor Bahru – Safe Product Verification<\/mark><\/h2>\n\n\n\n
LENISNA is a specific injectable hybrid biostimulator developed by VAIM Co., Ltd. in South Korea, combining 170 mg of Poly-D,L-Lactic Acid (PDLLA) and 30 mg of non-crosslinked hyaluronic acid (HA). VAIM also identifies this higher-content formulation as JUVELOOK Volume in selected international markets. At Medi Clinic in Johor Bahru, we provide a doctor-led consultation to diagnose your facial soft-tissue volume loss, evaluate your skeletal anatomy, and determine if this specific PDLLA and HA treatment is suitable for your gradual tissue-remodelling goals.

Many adults from Singapore, Taman Molek, and Iskandar Puteri visit our clinic because we prioritise medical safety and exact-product transparency over automatic injectable packages. Before proceeding with any collagen-biostimulator consultation, we must verify the exact current Malaysia Medical Device Register (MDA) status, ensure the product is supplied by an authorised Malaysian representative, and confirm that the intended purpose matches your specific concerns whether that involves cheek-volume concerns, temple hollowing, or selected atrophic acne scars.<\/div>\n\n<\/div>\n\n
\n\n
\"\"<\/figure>\n\n<\/div>\n<\/div>\n<\/div>
\n
\n
\n\n
Understanding PDLLA and HA<\/div>\n\n\n\n

How LENISNA & JUVELOOK Volume Work<\/mark><\/h2>\n\n\n\n
LENISNA is positioned as a hybrid biostimulator. It contains porous microspheres of PDLLA a biodegradable synthetic polymer suspended in a non-crosslinked HA carrier. Following injection, the HA component may provide early temporary hydration and fullness. Over time, the PDLLA particles create a controlled inflammatory tissue response intended to support fibroblast activity and gradual collagen-related tissue remodelling.

It is critical to understand that LENISNA is not<\/strong> the same as standard JUVELOOK. Standard JUVELOOK contains only 42.5 mg of PDLLA and 7.5 mg of HA, and is typically positioned for superficial skin-quality concerns. LENISNA (or JUVELOOK Volume) is a much higher-content formulation (170 mg PDLLA) designed for more pronounced facial deflation and volume goals. Furthermore, LENISNA is not a conventional crosslinked HA filler (like JUV\u00c9DERM), it is not a PN product (like Rejuran), and it is not a stem-cell treatment. Patients visiting our JB clinic from Mount Austin or across the Causeway appreciate our transparent explanation that PDLLA research supports a plausible gradual biostimulatory effect, but exact volume improvements remain variable and product-specific.<\/div>\n\n<\/div>\n\n
\n\n
\"Diagram<\/figure>\n\n<\/div>\n<\/div>\n<\/div>
\n
\n
\n\n
\"Doctor<\/figure>\n\n<\/div>\n\n
\n\n
Proper Medical Assessment<\/div>\n\n\n\n

Evaluating Suitability for Facial Volume Goals<\/mark><\/h2>\n\n\n\n
Because LENISNA involves gradual tissue response and is not a fully reversible HA filler, a thorough doctor-led assessment is mandatory.

Anatomical Assessment:<\/strong> We assess your facial skeletal structure, fat compartments, skin laxity, and muscle activity. Volume loss in areas like the cheeks, temples (an anatomically advanced vascular area), and selected nasolabial folds or marionette areas often requires careful planning. We also assess selected atrophic acne scars, distinguishing between rolling, boxcar, or tethered scars which may require different interventions.

LENISNA is intended for selected adults with realistic expectations. We do not market this treatment to minors, nor do we perform it for creating a guaranteed V-shaped face, copying social media trends, or replacing a surgical facelift. Patients with active infections, unresolved nodules from previous injectables, autoimmune conditions, or those who are pregnant must delay treatment.<\/div>\n\n<\/div>\n<\/div>\n<\/div>
\n
\n
\n\n
Managing Treatment Risks<\/div>\n\n\n\n

Understanding Complications & Aftercare<\/mark><\/h2>\n\n\n\n
All facial injectables carry medical risks. Common temporary reactions include redness, swelling, bruising, tenderness, and firmness at the injection site. More importantly, because LENISNA contains PDLLA particles, delayed inflammatory reactions such as persistent nodules or granulomas can occur weeks or months later. A published case report has also documented a nodular reaction following JUVELOOK Volume use in the delicate tear-trough area, demonstrating that under-eye treatment is not risk-free.

Like any injectable, unintended entry into a facial artery (vascular occlusion) can cause severe tissue necrosis, scarring, or rare catastrophic events such as visual impairment, blindness, or stroke. You must seek immediate emergency care if you experience severe pain, pale or dusky skin, blistering, or sudden visual changes. Furthermore, LENISNA is not fully reversible; while hyaluronidase can act on the HA carrier, it does not dissolve PDLLA particles. Your doctor will provide strict written aftercare, including avoiding unapproved facial devices and attending scheduled follow-ups.<\/div>\n\n<\/div>\n\n
\n\n
\"Doctor<\/figure>\n\n<\/div>\n<\/div>\n<\/div>
\n
\n
\n\n
\"Patient<\/figure>\n\n<\/div>\n\n
\n\n
Your Consultation Journey<\/div>\n\n\n\n

What to Expect From a LENISNA Assessment<\/mark><\/h2>\n\n\n\n
A responsible consultation at Medi Clinic involves a comprehensive review of your medical history, allergy profile, and any previous biostimulators (such as Sculptra, Radiesse, or AestheFill) or permanent fillers you may have received.

Exact-Product Verification:<\/strong> We must confirm current LENISNA or JUVELOOK Volume availability by verifying genuine sealed packaging, lot numbers, and exact Malaysia Medical Device Register (MDA) status from an authorised supplier. Overseas CE or Korean registrations do not automatically guarantee local intended-purpose approvals.

Treatment is never guaranteed on the same day. We do not sell fixed “vial packages” because session counts depend entirely on individual anatomical needs and tissue response. Our patients from Johor Bahru, Eko Galleria, and Singapore appreciate that we set realistic goals, explaining that LENISNA may support gradual facial-volume improvement, but permanent collagen or fat restoration cannot be guaranteed.<\/div>\n\n<\/div>\n<\/div>\n<\/div>
\n
\n
\n\n

Frequently Asked Questions About LENISNA Treatment in JB<\/mark><\/h2>\n\n\n\n
Here are answers to common questions about LENISNA, JUVELOOK Volume, PDLLA, and collagen biostimulators. This information helps you have an informed, safety-focused discussion with our doctor.<\/div>\n\n<\/div>\n<\/div>\n\n
\n
\n
\n\n

What is LENISNA?<\/h3>\n\n\n\n
LENISNA is an injectable product developed by VAIM Co., Ltd. combining 170 mg of Poly-D,L-Lactic Acid (PDLLA) and 30 mg of non-crosslinked hyaluronic acid (HA). It is positioned as a volume-focused biostimulator.<\/div>\n\n<\/div><\/div>\n\n
\n\n

Is LENISNA the same as standard JUVELOOK?<\/h3>\n\n\n\n
No. Standard JUVELOOK is a lower-content formulation containing 42.5 mg PDLLA and 7.5 mg HA, generally used for superficial skin concerns. They do not share the same treatment areas, protocols, or evidence.<\/div>\n\n<\/div><\/div>\n\n
\n\n

Is LENISNA the same as JUVELOOK Volume?<\/h3>\n\n\n\n
According to current VAIM information, LENISNA and JUVELOOK Volume are two names for the same 170 mg PDLLA formulation used in different markets. However, the exact Malaysian registration must always be verified before treatment.<\/div>\n\n<\/div><\/div>\n\n
\n\n

Is LENISNA the same as Sculptra or AestheFill?<\/h3>\n\n\n\n
No. Sculptra contains PLLA (Poly-L-Lactic Acid) and AestheFill is a separate PDLLA product from a different manufacturer. Each product has unique particle characteristics, clinical evidence, and preparation methods.<\/div>\n\n<\/div><\/div>\n\n
\n\n

Is LENISNA fully reversible?<\/h3>\n\n\n\n
No. While the enzyme hyaluronidase can affect the non-crosslinked HA carrier, it does not dissolve the PDLLA particles. A complete return to your original appearance cannot be guaranteed, making precise doctor placement essential.<\/div>\n\n<\/div><\/div>\n\n
\n\n

Can LENISNA cause nodules?<\/h3>\n\n\n\n
Yes. Delayed inflammatory reactions, persistent nodules, or uncommon granulomatous inflammation can occur weeks or months after PDLLA treatment. Any delayed lumps or worsening swelling require prompt medical assessment.<\/div>\n\n<\/div><\/div>\n\n
\n\n

Can LENISNA be used under the eyes?<\/h3>\n\n\n\n
Under-eye use should not be automatically assumed. A published medical case report detailed a nodular reaction after JUVELOOK Volume was used for a tear-trough concern. The area is delicate, highly vascular, and requires extreme caution.<\/div>\n\n<\/div><\/div>\n\n
\n\n

Does LENISNA contain PN, exosomes, or stem cells?<\/h3>\n\n\n\n
No. LENISNA contains PDLLA and non-crosslinked HA. It is not a polynucleotide (PN\/PDRN) product like Rejuran, nor does it contain salmon DNA, living stem cells, or exosomes.<\/div>\n\n<\/div><\/div>\n\n
\n\n

Can Singapore patients come to JB for this consultation?<\/h3>\n\n\n\n
Yes. Medi Clinic actively serves visitors travelling via the Causeway and Tuas Second Link for doctor-led assessments. We strongly encourage you to bring your previous injectable records and disclose any prior biostimulators or hyaluronidase treatments.<\/div>\n\n<\/div><\/div>\n<\/div>\n<\/div>\n\n
\n
\n
\n
\n\n
\n